EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 07 2021
Historique:
received: 27 10 2020
accepted: 08 06 2021
entrez: 7 7 2021
pubmed: 8 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

The TMPRSS2-ERG gene fusion is the most frequent alteration observed in human prostate cancer. However, its role in disease progression is still unclear. In this study, we uncover an important mechanism promoting ERG oncogenic activity. We show that ERG is methylated by Enhancer of zest homolog 2 (EZH2) at a specific lysine residue (K362) located within the internal auto-inhibitory domain. Mechanistically, K362 methylation modifies intra-domain interactions, favors DNA binding and enhances ERG transcriptional activity. In a genetically engineered mouse model of ERG fusion-positive prostate cancer (Pb-Cre4 Pten

Identifiants

pubmed: 34230470
doi: 10.1038/s41467-021-24380-6
pii: 10.1038/s41467-021-24380-6
pmc: PMC8260656
doi:

Substances chimiques

ERG protein, mouse 0
Oncogene Proteins 0
Oncogene Proteins, Fusion 0
TMPRSS2-ERG fusion protein, human 0
Trans-Activators 0
Transcription Factors 0
Transcriptional Regulator ERG 0
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43
Ezh2 protein, mouse EC 2.1.1.43
Serine Endopeptidases EC 3.4.21.-
TMPRSS2 protein, mouse EC 3.4.21.-
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4147

Références

J Vis Exp. 2011 May 30;(51):
pubmed: 21673636
Nat Genet. 2009 May;41(5):524-6
pubmed: 19396167
Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37
pubmed: 11715049
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
Genome Res. 2012 Sep;22(9):1760-74
pubmed: 22955987
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Nat Med. 2013 Aug;19(8):1023-9
pubmed: 23817021
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Mol Cell. 2012 Nov 30;48(4):572-86
pubmed: 23063525
Cell Rep. 2018 Dec 4;25(10):2808-2820.e4
pubmed: 30517868
Nat Genet. 2009 May;41(5):619-24
pubmed: 19396168
Mol Cell. 2015 Mar 5;57(5):769-783
pubmed: 25620564
Oncogene. 2007 Apr 19;26(18):2667-73
pubmed: 17043636
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Cancer Res. 2012 Jun 1;72(11):2889-900
pubmed: 22505649
Oncotarget. 2016 Nov 22;7(47):76756-76768
pubmed: 27732936
J Phys Chem B. 2008 Jul 31;112(30):9020-41
pubmed: 18593145
Cell. 2006 Apr 21;125(2):301-13
pubmed: 16630818
Cancer Cell. 2008 Mar;13(3):221-34
pubmed: 18328426
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10
pubmed: 18245377
Cancer Cell. 2013 Jun 10;23(6):839-52
pubmed: 23684459
BMC Med Genomics. 2010 Mar 16;3:8
pubmed: 20233430
J Chem Inf Model. 2016 Oct 24;56(10):1950-1962
pubmed: 27599150
J Vis Exp. 2009 Nov 30;(33):
pubmed: 19949373
J Biol Chem. 2017 Oct 20;292(42):17225-17235
pubmed: 28887309
Nat Rev Cancer. 2008 Jul;8(7):497-511
pubmed: 18563191
Prostate. 2014 Nov;74(15):1481-7
pubmed: 25175352
Cell Res. 2011 Mar;21(3):375-80
pubmed: 21151202
Science. 2012 Dec 14;338(6113):1465-9
pubmed: 23239736
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
pubmed: 19116269
J Am Chem Soc. 2009 Oct 7;131(39):13894-5
pubmed: 19739624
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Biophys J. 2012 Apr 18;102(8):1926-33
pubmed: 22768949
Genome Biol. 2008;9(9):R137
pubmed: 18798982
J Comput Chem. 2014 May 30;35(14):1101-5
pubmed: 24676684
Nat Rev Cancer. 2015 Feb;15(2):110-24
pubmed: 25614009
Histochem Cell Biol. 2008 Dec;130(6):1119-30
pubmed: 19005674
Nature. 2014 Jun 12;510(7504):278-82
pubmed: 24759320
Science. 2005 Oct 14;310(5746):306-10
pubmed: 16224021
Mol Cell. 2017 Dec 7;68(5):872-884.e6
pubmed: 29153392
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
EMBO J. 2012 Jun 13;31(12):2810-23
pubmed: 22531786
Neoplasia. 2008 Feb;10(2):177-88
pubmed: 18283340
Cancer Res. 2013 Jul 15;73(14):4533-47
pubmed: 23687337
Cancer Cell. 2010 May 18;17(5):443-54
pubmed: 20478527
Mol Cell. 2011 Sep 2;43(5):798-810
pubmed: 21884980
Cancer Cell. 2018 Jul 9;34(1):103-118.e9
pubmed: 30008322
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13374-9
pubmed: 23898196
Nat Commun. 2014 Nov 21;5:5383
pubmed: 25415230

Auteurs

Marita Zoma (M)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Laura Curti (L)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia (IIT), Milan, Italy.

Dheeraj Shinde (D)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Domenico Albino (D)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Abhishek Mitra (A)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Jacopo Sgrignani (J)

Università della Svizzera Italiana (USI), Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland.

Sarah N Mapelli (SN)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.

Giada Sandrini (G)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.

Gianluca Civenni (G)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Jessica Merulla (J)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Giovanna Chiorino (G)

Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy.

Paolo Kunderfranco (P)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.
Humanitas Research Center, Milan, Italy.

Alessia Cacciatore (A)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Aleksandra Kokanovic (A)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Andrea Rinaldi (A)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Andrea Cavalli (A)

Università della Svizzera Italiana (USI), Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland.

Carlo V Catapano (CV)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Giuseppina M Carbone (GM)

Università della Svizzera italiana (USI), Institute of Oncology Research (IOR), Bellinzona, Switzerland. pina.carbone@ior.usi.ch.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH